silevertinib in combination with temozolomide

Drug identity checked against registry records

Also recorded as BDTX-1535; TMZ; Temodar

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIINCT07326566BDTXPhase 2Recruiting2028-11Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.